Claudia Höbartner

Dr. Claudia Höbartner

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2021 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
FKFlorian Kabinger
Florian Kabinger
CSCarina Stiller
Carina Stiller
JSJana Schmitzová
Jana Schmitzová
CDChristian Dienemann
Christian Dienemann
GKGoran Kokic
Goran Kokic
PCPatrick Cramer
Patrick Cramer
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, we establish the molecular mechanisms underlying molnupiravir-induced RNA mutagenesis by the viral RNA-dependent RNA polymerase (RdRp). Biochemical assays show that the RdRp uses the active form of molnupiravir, β-d-N4-hydroxycytidine (NHC) triphosphate, as a substrate instead of cytidine triphosphate or uridine triphosphate. When the RdRp uses the resulting RNA as a template, NHC directs incorporation of either G or A, leading to mutated RNA products. Structural analysis of RdRp–RNA complexes that contain mutagenesis products shows that NHC can form stable base pairs with either G or A in the RdRp active center, explaining how the polymerase escapes proofreading and synthesizes mutated RNA. This two-step mutagenesis mechanism probably applies to various viral polymerases and can explain the broad-spectrum antiviral activity of molnupiravir.

19 October 2017 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
AWAhmed S Warda
Ahmed S Warda
JKJens Kretschmer
Jens Kretschmer
PHPhilipp Hackert
Philipp Hackert
CLChristof Lenz
Christof Lenz
HUHenning Urlaub
Henning Urlaub
MBMarkus T. Bohnsack
Markus T. Bohnsack

12 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GKGoran Kokic
Goran Kokic
HHHauke S. Hillen
Hauke S. Hillen
DTDimitry Tegunov
Dimitry Tegunov
CDChristian Dienemann
Christian Dienemann
FSFlorian Seitz
Florian Seitz
PCPatrick Cramer
Patrick Cramer
Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls. Here we use synthetic RNA chemistry, biochemistry and cryo-electron microscopy to establish the molecular mechanism of remdesivir-induced RdRp stalling. We show that addition of the fourth nucleotide following remdesivir incorporation into the RNA product is impaired by a barrier to further RNA translocation. This translocation barrier causes retention of the RNA 3ʹ-nucleotide in the substrate-binding site of the RdRp and interferes with entry of the next nucleoside triphosphate, thereby stalling RdRp. In the structure of the remdesivir-stalled state, the 3ʹ-nucleotide of the RNA product is matched and located with the template base in the active center, and this may impair proofreading by the viral 3ʹ-exonuclease. These mechanistic insights should facilitate the quest for improved antivirals that target coronavirus replication.

1 December 2004 in Chemistry & Biology
Verified
Journal Article
Closed access
Alexander SerganovAlexander Serganov
Alexander Serganov
YYYu-Ren Yuan
Yu-Ren Yuan
OPOlga Pikovskaya
Olga Pikovskaya
APAnna Polonskaia
Anna Polonskaia
LMLucy Malinina
Lucy Malinina
DPDinshaw J. Patel
Dinshaw J. Patel

30 January 2019 in Genes
Verified
Journal Article
Open access
PDF file
KSKatherine E. Sloan
Katherine E. Sloan
CHClaudia Höbartner
Claudia Höbartner
MBMarkus T. Bohnsack
Markus T. Bohnsack
5-methylcytosine (m5C) is an abundant RNA modification that’s presence is reported in a wide variety of RNA species, including cytoplasmic and mitochondrial ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs), as well as messenger RNAs (mRNAs), enhancer RNAs (eRNAs) and a number of non-coding RNAs. In eukaryotes, C5 methylation of RNA cytosines is catalyzed by enzymes of the NOL1/NOP2/SUN domain (NSUN) family, as well as the DNA methyltransferase homologue DNMT2. In recent years, substrate RNAs and modification target nucleotides for each of these methyltransferases have been identified, and structural and biochemical analyses have provided the first insights into how each of these enzymes achieves target specificity. Functional characterizations of these proteins and the modifications they install have revealed important roles in diverse aspects of both mitochondrial and nuclear gene expression. Importantly, this knowledge has enabled a better understanding of the molecular basis of a number of diseases caused by mutations in the genes encoding m5C methyltransferases or changes in the expression level of these enzymes.

14 December 2008 in Nature Nanotechnology
Verified
Journal Article
Closed access
DHDaniel A. Heller
Daniel A. Heller
HJHong Jin
Hong Jin
BMBrittany M. Martinez
Brittany M. Martinez
DPDhaval Patel
Dhaval Patel
BMBrigid M. Miller
Brigid M. Miller
MSMichael S. Strano
Michael S. Strano